1.47
Can-Fite Biopharma Ltd ADR Borsa (CANF) Ultime notizie
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits - GlobeNewswire Inc.
USC Law Launches New Online Certificate in Dispute Resolution - Business Wire
Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions - Business Wire
Cronos Group Inc (NASDAQ: CRON) Could Slash -12.75% Soon - Stocks Register
Commercial Metals Co (NYSE: CMC) Could Slash -1.03% Soon - Stocks Register
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Reckitt Benckiser Group PLC (OTC: RBGLY) - Business Wire
Can Fite Biopharma stock hits 52-week low at $1.86 - Investing.com India
Can-Fite secures Australian patent for obesity treatment - Investing.com
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of WeRide Inc. - Business Wire
Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com India
Ratios in Focus: Analyzing Can-Fite Biopharma Ltd ADR (CANF)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Analytical Lens: Exploring Can-Fite Biopharma Ltd ADR (CANF)’s Financial Story Through Ratios - The Dwinnex
List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel
Wearable Devices Ltd. sets annual meeting for September 26 - Investing.com
Martingale Risk – Philips Shareholders Group Action to be Filed in the Netherlands - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire UK
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
bioAffinity Technologies Inc Stock Price Today | NASDAQ: BIAF Live - Investing.com
NOVONIX to Commence Trading on Nasdaq through Level II ADR Program - Business Wire
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma - Business Wire
4 Penny Stocks On Robinhood To Buy Under $4 Now; Worth The Risk? - Penny Stocks
Can-Fite BioPharma (CANF) Stock Price, News & Analysis - MarketBeat
New Lenovo Research: People are Working More by Not Going to Work, but Worry about Home Tech, Data Security and Personal Costs - Business Wire
Global Metal Casting Market 2020-2024 | Evolving Opportunities with Acast and Alcast Co. | Technavio - Business Wire
10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance
Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha
letgo Raises $100 Million in Series A Funding from Naspers - Business Wire
Ipsen Announces That Its Controlling Shareholder, Mayroy, Sold Approximately 7% of Ipsen’s Share Capital via Private Placement - Business Wire
Can-Fite BioPharma Begins Trading in U.S. through Launch of ADRs - CNBC
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):